Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Data from Merck, Daiichi could support first approval for HER3 ADC

In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more

September 18, 2024 1:26 AM UTC

New progression-free survival results from the Phase III HERTHENA-Lung02 study add to the body of evidence that could support the first approval of patritumab deruxtecan (HER3-DXd).

The antibody-drug conjugate from Merck & Co. Inc. (NYSE:MRK) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) led to a significant improvement in progression-free survival (PFS) compared with chemotherapy, meeting the trial’s primary endpoint, among patients with EGFR-mutant non-small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor treatment...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article